ArticleFrontiers in oncology2026

Acquired TPM3::NTRK1 fusion as a novel off-target resistance mechanism to selpercatinib in RET-positive lung adenocarcinoma: a case report.

Ritwika Choudhury et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.